Gilead trumpets data with newly-bought magrolimab in blood cancersJust three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the Share XGilead trumpets data with newly-bought magrolimab in blood cancershttps://pharmaphorum.com/news/gilead-magrolimab-blood-cancer-asco/
